Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation
Journal of Hepatology2016Vol. 65(1), pp. 17–25
Citations Over TimeTop 1% of 2016 papers
Natasha K. Martin, Peter Vickerman, Gregory J. Dore, Jason Grebely, Alec Miners, John Cairns, Graham R. Foster, Sharon Hutchinson, David Goldberg, Thomas Martin, Mary Ramsay, Matthew Hickman
Abstract
Treating PWID with moderate or mild HCV with IFN-free DAAs is cost-effective compared to delay until cirrhosis, except when chronic HCV prevalence and reinfection risk is very high.
Related Papers
- Susquehanna Chorale Spring Concert "Roots and Wings"(2017)
- → DETERMINING QUALITY REQUIREMENTS AT THE UNIVERSITIES TO IMPROVE THE QUALITY OF EDUCATION(2018)
- → Genentech taps Affimed’s antibodies(2018)
- Enxerto livre de arteria epigastrica inferior: avaliacao hemodinamica e angiografica pre e pos-operatoria(1988)
- → KOMPLIKASI REGIONAL ANESTESI PADA PEDIATRIK(2023)